We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Economic evaluations in the canadian common drug review.
- Authors
Laupacis, Andreas
- Abstract
The Canadian Common Drug Review (CDR) was established in 2003 to provide a single process for making formulary recommendations to most Canadian publicly funded drug plans. This paper considers the most common challenges faced by the CDR: (a) determining the effectiveness of a drug (particularly interpreting the importance of surrogate markers and changes in QOL measures); (b) the massive rise in the cost of new drugs, which, in general, does not seem to accompanied by a massive increase in effectiveness; (c) interpreting complex pharmacoeconomic evaluations which often do not provide straightforward answers about the cost effectiveness of a drug; (d) prescription creep (the tendency for drugs in the real world to be used in patients who were not studied in clinical trials, thus raising concerns about a drug's real-world cost effectiveness; and (e) ethical and societal issues, particularly the reimbursement of expensive drugs for rare diseases.
- Subjects
CANADA; COST effectiveness; MEDICAL economics; DRUG efficacy; CLINICAL trials; RARE diseases; MEDICAL prescriptions; PHARMACEUTICAL services insurance; MEDICAL care costs; PHARMACY; TREATMENT effectiveness; STANDARDS; ECONOMICS
- Publication
PharmacoEconomics, 2006, Vol 24, Issue 11, p1157
- ISSN
1170-7690
- Publication type
journal article
- DOI
10.2165/00019053-200624110-00011